Quarterly ResultAug 5, 2026, 04:32 PM
BillionToOne Q2 Revenue Jumps 64% to $109.4M; Net Income $8.1M
AI Summary
BillionToOne reported strong financial results for the second quarter ended June 30, 2026, with total revenue increasing 64% year-over-year to $109.4 million and achieving a net income of $8.1 million. The company also saw significant growth in both prenatal and oncology clinical testing revenue, alongside an improved gross profit margin of 70% and positive free cash flow of $5.1 million. BillionToOne reiterated its full-year 2026 revenue guidance of $450 million to $465 million and announced upcoming expansions and launches for its Unity Fetal Risk Screen and Northstar Origin products.
Key Highlights
- Total revenue was $109.4 million in Q2 2026, a 64% increase YoY.
- Net income reached $8.1 million, or $0.15 per diluted share in Q2 2026.
- Gross profit margin improved to 70% in Q2 2026, up 5 percentage points YoY.
- Income from operations was $5.5 million in Q2 2026, compared to a $1.6 million loss YoY.
- Free cash flow was $5.1 million in Q2 2026.
- Reiterated 2026 full-year revenue guidance of $450 million to $465 million.
- Expanded Unity Fetal Risk Screen with 130-gene panel to launch on August 17, 2026.
- Northstar Origin, an add-on tissue-of-origin feature, planned for launch on September 1, 2026.
Price Impact
More from BLLN